The U.S. Food and Drug Administration approved on Tuesday the first drug under its new fast-track program designed to shorten ...

An announcement from Praxis Precision Medicines ( ($PRAX) ) is now available. On December 9, 2025, Praxis Precision Medicines ...

Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli ...

Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a ...

Disc Medicine Inc. (NASDAQ: IRON) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, ...

Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli Lilly's experimental ...

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis ...

Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, ...

Ocular Therapeutix surged to a new four-year high on Monday after rallying for four consecutive days, with investor sentiment ...

Abivax receives a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ...

The agency is approaching the new overhaul as a chance to reshape drug regulations in the European Union.

The breakthrough could be used in a new vaccine or antibody therapy to fight mpox, the disease caused by the monkeypox virus.